Browse articles from EyeWorld.org related to presbyopia. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
➤ Topline Phase 3 pivotal study for BRIMOCHOL for treatment of presbyopia
➤ Positive Phase 2b/3 results for oral treatment of thyroid eye disease
➤ Clinical plan for first-in-human trial for investigational dry AMD therapy
➤ Update on registrational program therapy targeting various retinal diseases
➤ Collaboration to develop RNAi program targeting geographic atrophy
➤ ASCRS news and events
➤ Topline Phase 3 results for sublingual, opioid-free sedation
➤ Phase 1 results for non-surgical cell therapy for corneal edema
➤ First Phase 2 study evaluates wet AMD gene therapy in both eyes of patients
➤ Update on Phase 3 study evaluating treatment for progressive myopia
➤ FDA to review NDA for first-in-class dry eye treatment
➤ Enrollment complete for Phase 1/2 study evaluating novel IOP-lowering drug delivery platform
➤ ASCRS news and events
➤ Positive topline Phase 3 data for presbyopia drop
➤ Topline results for oral therapy targeting geographic atrophy
➤ Positive topline results from Phase 2 sustained-delivery drug for DME
➤ Study assesses new virtual reality simulator for phaco
➤ ASCRS news and events
➤ Whole-eye transplant 1 year later
➤ Phase 3 trial investigating new presbyopia drop therapy begins
➤ Study reports on multi-interventional glaucoma technique
➤ Topline results from Phase 3 trial for drug for active thyroid eye disease
➤ Pilot study complete for AMD treatment
➤ ASCRS news and events
➤ NDA submitted for presbyopia treatment
➤ FDA approves AMD treatment
➤ Primary endpoint achieved in Phase 3 trial of reproxalap for dry eye
➤ Clinical trial results that supported new excimer laser approval published
➤ Company updates on several clinical trials
➤ First patient dosed in Phase 2 trial for intravitreal steroid implant for DME treatment
➤ ASCRS news and events
While there a lot of different technologies that can give patients excellent refractive results after cataract surgery, this area keeps expanding and improving. As more options become available, it increases the complexity of talking to patients. This is what the symposium Having “The Talk” focused on at the 2024 ASCRS Annual Meeting.
➤ Phase 3 results for new corticosteroid
➤ Positive topline results from Phase 3 trials investigating presbyopia drop
➤ Phase 2 data presented for IOP-lowering intracameral implant
➤ First patient dosed in retinitis pigmentosa gene therapy
➤ Survey shows burden of pterygium
➤ ASCRS news and events
➤ FDA approves updated femtosecond laser for refractive surgery
➤ Positive topline results from Phase 3, first-in-class dry eye disease studies
➤ Rare Disease Designation granted for investigational gene therapy
➤ Positive interim data for investigational Stargardt disease treatment
➤ First patient dosed in Phase 2 trial for DME treatment
➤ Research program established to investigate whole eye transplant
➤ ASCRS news and events
John Marshall, MD, PhD, discusses work being done on laser scleral microporation, a technique that he thinks could “rejuvenate” the eye’s natural dynamically focusing process.
➤ FDA approves presbyopia drop
➤ FDA approves expanded capabilities on anterior segment diagnostic platform
➤ Phase 4 data presented for dry eye disease drug
➤ Extension study for investigational wet AMD treatment demonstrates safety, efficacy
➤ Reports suggest reproxalap NDA might not be approved
➤ Companies partner to develop gene therapy
➤ ASCRS news and events
